Jun-24-22 09:03AM | |
May-25-22 12:00PM | |
May-18-22 07:30AM | |
May-04-22 04:30PM | |
Apr-22-22 07:30AM | |
Apr-08-22 05:00PM | |
Mar-15-22 07:30AM | |
Mar-10-22 06:35PM | |
Feb-28-22 07:30AM | |
Jan-14-22 05:43AM | |
Jan-04-22 07:30AM | |
Dec-28-21 02:38AM | |
Dec-09-21 01:18PM | |
07:30AM | |
Nov-30-21 05:53AM | |
Nov-15-21 12:25PM | |
07:30AM | |
Nov-09-21 07:30AM | |
Nov-08-21 03:00PM | |
Oct-27-21 07:30AM | |
Oct-21-21 07:30AM | |
Oct-01-21 08:23AM | |
Sep-22-21 11:18AM | |
07:30AM | |
Sep-08-21 07:30AM | |
Aug-30-21 05:10PM | |
Aug-12-21 04:06PM | |
08:45AM | |
07:30AM | |
Aug-04-21 03:00PM | |
Aug-02-21 03:05PM | |
02:30PM | |
12:30PM | |
12:30PM | |
11:00AM | |
10:00AM | |
09:16AM | |
09:09AM | |
05:50AM | |
03:27AM | |
Aug-01-21 10:38AM | |
06:36AM | |
Jul-30-21 08:49PM | |
07:19PM | |
07:10PM | |
05:15PM | |
02:57PM | |
01:30PM | |
12:40PM | |
11:30AM | |
11:30AM | |
11:00AM | |
10:00AM | |
10:00AM | |
09:30AM | |
09:00AM | |
05:18AM | |
Jul-29-21 08:47PM | |
05:29PM | |
04:02PM | |
01:15PM | |
12:30PM | |
10:45AM | |
10:00AM | |
09:24AM | |
05:27AM | |
Jul-28-21 08:00PM | |
07:25PM | |
07:07PM | |
05:34PM | |
03:16PM | |
01:45PM | |
01:35PM | |
01:15PM | |
12:30PM | |
11:00AM | |
10:00AM | |
09:33AM | |
09:30AM | |
09:07AM | |
Jul-27-21 06:24PM | |
05:32PM | |
12:45PM | |
11:15AM | |
11:14AM | |
10:40AM | |
09:49AM | |
09:00AM | |
05:40AM | |
12:50AM | |
Jul-26-21 09:45PM | |
08:10PM | |
06:58PM | |
05:28PM | |
03:48PM | |
03:23PM | |
02:12PM | |
01:55PM | |
01:00PM | |
12:10PM | |
|
|
|
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Loose Christopher R. | Chief Scientific Officer | Feb 22 | Sale | 3.53 | 1,069 | 3,774 | 34,827 | Feb 23 04:41 PM | LeBel Carl | Chief Development Officer | Feb 22 | Sale | 3.53 | 1,069 | 3,773 | 11,126 | Feb 23 04:36 PM | PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 22 | Sale | 3.53 | 1,542 | 5,442 | 8,927 | Feb 23 04:38 PM | McCubbin Quentin | Chief Manufacturing Officer | Feb 22 | Sale | 3.53 | 1,584 | 5,598 | 22,771 | Feb 23 04:34 PM | Arnold Wendy S | Chief People Officer | Feb 22 | Sale | 3.53 | 1,326 | 4,683 | 11,824 | Feb 23 04:32 PM | Arnold Wendy S | Chief People Officer | Feb 18 | Sale | 3.87 | 1,209 | 4,684 | 13,150 | Feb 23 04:32 PM | McCubbin Quentin | Chief Manufacturing Officer | Feb 18 | Sale | 3.87 | 1,411 | 5,463 | 24,355 | Feb 23 04:34 PM | PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 18 | Sale | 3.88 | 1,404 | 5,443 | 10,469 | Feb 23 04:38 PM | LeBel Carl | Chief Development Officer | Feb 18 | Sale | 3.87 | 974 | 3,772 | 12,195 | Feb 23 04:36 PM | Loose Christopher R. | Chief Scientific Officer | Feb 18 | Sale | 3.87 | 974 | 3,772 | 35,896 | Feb 23 04:41 PM | Arnold Wendy S | Chief People Officer | Feb 17 | Sale | 4.19 | 1,118 | 4,688 | 14,359 | Feb 18 04:08 PM | LeBel Carl | Chief Development Officer | Feb 17 | Sale | 4.19 | 901 | 3,774 | 13,169 | Feb 18 04:12 PM | McCubbin Quentin | Chief Manufacturing Officer | Feb 17 | Sale | 4.20 | 1,303 | 5,467 | 25,766 | Feb 18 04:10 PM | PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 17 | Sale | 4.20 | 1,296 | 5,443 | 11,873 | Feb 18 04:14 PM | Loose Christopher R. | Chief Scientific Officer | Feb 17 | Sale | 4.19 | 900 | 3,774 | 36,870 | Feb 18 04:13 PM | Loose Christopher R. | Chief Scientific Officer | Feb 16 | Sale | 4.43 | 851 | 3,769 | 37,770 | Feb 18 04:13 PM | PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 16 | Sale | 4.43 | 1,229 | 5,443 | 13,169 | Feb 18 04:14 PM | McCubbin Quentin | Chief Manufacturing Officer | Feb 16 | Sale | 4.43 | 1,233 | 5,461 | 27,069 | Feb 18 04:10 PM | LeBel Carl | Chief Development Officer | Feb 16 | Sale | 4.43 | 831 | 3,680 | 14,070 | Feb 18 04:12 PM | Arnold Wendy S | Chief People Officer | Feb 16 | Sale | 4.43 | 1,057 | 4,681 | 15,477 | Feb 18 04:08 PM | LeBel Carl | Chief Development Officer | Feb 15 | Sale | 4.33 | 844 | 3,655 | 14,901 | Feb 16 05:05 PM | McCubbin Quentin | Chief Manufacturing Officer | Feb 15 | Sale | 4.33 | 1,261 | 5,461 | 28,302 | Feb 16 05:04 PM | Loose Christopher R. | Chief Scientific Officer | Feb 15 | Sale | 4.33 | 863 | 3,738 | 38,621 | Feb 16 05:02 PM | PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 15 | Sale | 4.33 | 1,347 | 5,834 | 14,398 | Feb 16 04:59 PM | Arnold Wendy S | Chief People Officer | Feb 15 | Sale | 4.33 | 1,168 | 5,059 | 16,534 | Feb 16 04:50 PM | Lucchino David L. | President and CEO | Jan 18 | Option Exercise | 0.61 | 6,905 | 4,212 | 470,111 | Jan 20 08:33 AM | Lucchino David L. | President and CEO | Dec 20 | Option Exercise | 0.61 | 6,905 | 4,212 | 463,206 | Dec 21 05:03 PM | Lucchino David L. | President and CEO | Nov 02 | Option Exercise | 0.61 | 6,905 | 4,212 | 456,301 | Nov 04 05:48 PM | Lucchino David L. | President and CEO | Oct 05 | Option Exercise | 0.61 | 6,905 | 4,212 | 449,396 | Oct 07 04:13 PM | Lucchino David L. | President and CEO | Sep 03 | Option Exercise | 0.61 | 6,905 | 4,212 | 442,491 | Sep 08 05:06 PM | Lucchino David L. | President and CEO | Aug 03 | Option Exercise | 0.61 | 6,905 | 4,212 | 435,586 | Aug 05 05:08 PM | Lucchino David L. | President and CEO | Jul 01 | Option Exercise | 0.61 | 6,905 | 4,212 | 428,681 | Jul 06 04:22 PM |
|